Weather , , 0°C

Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight

 Breaking News
  • No posts were found

Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight

February 20
18:44 2021
Trastuzumab Biosimilar Landscape Report 2020 by DelveInsight

DelveInsight Business Research LLP
DelveInsight’s, “Trastuzumab– Biosimilar Insight, 2020,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight launched a new report on Trastuzumab Biosimilar Insights 2020.

DelveInsight’s, “Trastuzumab Biosimilar Insight, 2020,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in the Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Trastuzumab Overview:

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medications. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.

Click here and get access to free sample pages of the report. 

Trastuzumab Marketed drugs:

  • Kanjinti by Amgen 
  • Herzuma by Celltrion

Trastuzumab Emerging drugs:

  • EG12014 by EirGenix 
  • HD201 by Prestige BioPharma

Pipeline Development Activities

The report covers detailed information of collaborations, acquisition, and merger, licensing along a thorough therapeutic assessment of emerging Trastuzumab biosimilar drugs.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/trastuzumab-biosimilars-insight

Table of contents:

1. Key Insights

2. Trastuzumab Biosimilars: Snapshot

3. Executive Summary

4. Regulatory Outlook For Biosimilars

5. Trastuzumab (Reference Product: Herceptin)

6. Research and Development

7. Herceptin Biosimilar: Emerging Opportunities

8. Trastuzumab: Biosimilars Assessment

9. Trastuzumab Biosimilars Profiles: By Company

10. Trastuzumab Biosimilars: Comparative Landscape: By Company

11. Trastuzumab Biosimilars: Competitive Landscape

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Download our full report: https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

February 2021
M T W T F S S
1234567
891011121314
15161718192021
22232425262728

Categories